COMPUTEX
31.5.2021 08:31:06 CEST | Business Wire | Press release
COMPUTEX kicked off this year’s month-long #COMPUTEXVirtual on May 31 with James Huang, TAITRA Chairman, highlighting the not-to-be-missed events. Michelle Johnston Holthaus, Intel Executive Vice President, Chief Revenue Officer, discussed accelerating digital transformation and how to release a new era of innovation when the world is most looking forward to innovation. On the same day, Arm CEO Simon Segars discussed the role of technology in the post-pandemic. Using examples from Arm's ecosystem partners, Segars demonstrated how technology could be a remarkable force for good that will be critical to the world’s recovery and create a more sustainable and secure future. Breaking away from traditions, COMPUTEX 2021 Virtual is an all-virtual exhibition, using AI platforms and leading the way to create a prosperous technology ecosystem.
“COMPUTEX was born in the 1980s when the technology industry took off. At that time, together with entrepreneurs from around the world, Taiwan pursued disruptive innovation and created an industry supply chain that paved the way for the Internet and digital economy that we have today. It has been one year into the pandemic, and we continue to push forward with innovation and navigate in the new normal. As Taiwan stands at the center of the global technology ecosystem, we will never cease to build, connect, integrate, innovate, and push forward with the latest technologies. Today, I am honored to announce the opening of #COMPUTEXVirtual. No matter where we are, let COMPUTEX connect us for a better future,” said James Huang, TAITRA Chairman.
COMPUTEX 2021 Opening Keynote by Intel is led by Executive Vice President and Chief Revenue Officer Michelle Johnston Holthaus with the theme of "Innovation Unleashed". Intel talks about sustainability awareness of enterprises under the raging global pandemic and how we continue to work with global partners to promote digital transformation; Intel not only response to the global market demand quickly and flexibly with the IDM 2.0 business model, but it also continues to promote innovation with 5G and its Open Architecture. We will also unveil new products leading in performance and enrich people’s user experience.
Arm CEO Simon Segars’ keynote titled “Sparking the World’s Post-Pandemic Recovery” demonstrated how technology can be a remarkable force for good that will be critical to the world’s recovery and create a more sustainable and secure future. The combination of computing in the age of AI will accelerate how we tackle complex challenges surrounding climate change, security, and equitable access to technologies and connectivity. Segars indicated that long-term investments in research and development are the key to shaping that future. Arm has invested significant resources in its next-generation architecture. Armv9 will enable partners to solve hard problems in the next decade of compute related to security, compute efficiency, and AI-enabled services, all while fighting climate change at the same time.
A Variety of Events for an All-New Virtual Experience
COMPUTEX 2021 Virtual offers live demonstration of the latest solutions on 5G, AI & IoT, Edge Computing, High-Performance Computing (HPC), Gaming, and Innovations and Startups.
The month-long online exhibition also includes a variety of events, including the #COMPUTEXVirtual online exhibition, COMPUTEX CEO Keynote, COMPUTEX Keynote, COMPUTEX & InnoVEX Forum, and COMPUTEX Matchmaking, giving attendees direct access to the leading tech manufacturers and the latest technology trends. The exhibition also enables the exhibitors to effectively seize business opportunities through the online matchmaking platform.
The #COMPUTEXVirtual online exhibition features Tech Insights, Virtual Displays, Matchmaking and Networking, and Hyper-Personalized Recommendations. #InnoVEXVirtual, the exclusive exhibit for startups, offers vibrant synergy on the other hand. #COMPUTEXVirtual is now open until June 30 midnight. Register now for free at: https://virtual.computextaipei.com.tw/
For more updates:
COMPUTEX website: https://www.computextaipei.com.tw/
InnoVEX website : https://www.innovex.com.tw/
About COMPUTEX TAIPEI (also called COMPUTEX):
Established in 1981, COMPUTEX is one of the leading global ICT, IoT, and startup tradeshows with a complete supply chain and IoT ecosystems. Co-organized by the Taiwan External Trade Development Council (TAITRA) and Taipei Computer Association (TCA), COMPUTEX, based upon Taiwan’s complete ICT clusters, covers the whole spectrum of the ICT industry, from established brands to startups and from ICT supply chain to IoT ecosystems. With strong R&D and manufacturing capabilities and IPR protection, Taiwan is a strategic destination for foreign companies and investors looking for partners in global technology ecosystems. Follow COMPUTEX on its website at www.computextaipei.com.tw and Twitter @computex_taipei using the hashtag #COMPUTEX.
About COMPUTEX 2021 Virtual:
As a pioneer in technology, COMPUTEX has been at the forefront in embracing digital transformation. In 2021, the show will go online. Together with the key global technology players, the organizer of COMPUTEX, Taiwan External Trade Development Council (TAITRA) introduces #COMPUTEXVirtual (including its global startups and innovations showcase #InnoVEXVirtual), an AI-driven virtual platform, and aims to deliver an exceptional virtual exhibition experience beyond the distance.
About TAITRA:
Founded in 1970, TAITRA is Taiwan's foremost nonprofit trade promoting organization. Sponsored by the government and industry organizations, TAITRA assists enterprises to expand their global reach. Headquartered in Taipei, TAITRA has a team of 1,300 specialists and operates 5 local offices in Taoyuan, Hsinchu, Taichung, Tainan and Kaohsiung, as well as 63 branches worldwide. Together with Taipei World Trade Center (TWTC) and Taiwan Trade Center (TTC), TAITRA has formed a global network dedicated to promoting world trade.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210530005044/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom